At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 482 enrolled
Drug / intervention
Dihydroergotaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Dihydroergotamine for Migraine and 2 related conditions. Completed, enrolled 482 participants across 44 sites.
Detailed Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, Migraine With Aura, Migraine Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartSep 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedMay 28, 2020
Enrollment StartSep 14, 2020
Primary CompletionJan 16, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.1 years ago
Interventions
Dihydroergotaminedrug
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.